Meeting
2023 ASCO Annual Meeting
ARID1A deficiency in triple-negative breast cancer induces adaptive immune resistance and sensitivity to immune checkpoint inhibitors.
Authors
Margaret Chen
Department of Breast Cancer and Urological Medical Oncology, Fudan University Shanghai Cancer Center, Department of Oncology, Shanghai Medical College, Fudan University, Shanghai, 200032, PR China, Shanghai, China
Margaret Chen , Bin Li , Ye Wang , Xichun Hu , Zhonghua Tao
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Breast Cancer—Metastatic
Track
Breast Cancer
Sub Track
Triple-Negative
Citation
J Clin Oncol 41, 2023 (suppl 16; abstr 1088)
DOI
10.1200/JCO.2023.41.16_suppl.1088
Abstract #
1088
Poster Bd #
309
Abstract Disclosures
Similar Posters
Poster
2020 Genitourinary Cancers Symposium
Integrative molecular characterization of sarcomatoid and rhabdoid renal cell carcinoma (S/R RCC) to reveal potential determinants of poor prognosis and response to immune checkpoint inhibitors (ICI).
First Author: Ziad Bakouny
Poster
2024 ASCO Genitourinary Cancers Symposium
AIM high: Epigenetic modulation and immune stimulation in bladder cancer.
First Author: Elizabeth Leone Koehne
Poster
2022 ASCO Annual Meeting
Comprehensive immune profiling unravels evolution of spatial distribution and immune repertoire in tumor microenvironment from primary to metastatic triple-negative breast cancer.
First Author: Weihua Guo
Poster
2021 ASCO Annual Meeting
Clinical performance of artificial intelligence-powered annotation of tumor cell PD-L1 expression for treatment of immune-checkpoint inhibitor (ICI) in advanced non-small cell lung cancer (NSCLC).
First Author: Hyojin Kim